Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion

Kadir Eltutar, Fahreddin Acar, Nurhan Dincer, Sibel Zirtiloglu, Erkan Unsal Istanbul Training and Research Hospital, Istanbul, Turkey Background: The purpose of this study was to evaluate the effects of intravitreal bevacizumab injection in the treatment of macular thickness and reduced visual acuit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Eltutar K, Acar F, Dincer N, Zirtiloglu S, Unsal E
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e4e3fc9a33de42bd8bbf69d9be4d4c90
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e4e3fc9a33de42bd8bbf69d9be4d4c90
record_format	dspace
spelling	oai:doaj.org-article:e4e3fc9a33de42bd8bbf69d9be4d4c902021-12-02T05:16:49ZEffects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion1177-54671177-5483https://doaj.org/article/e4e3fc9a33de42bd8bbf69d9be4d4c902013-09-01T00:00:00Zhttp://www.dovepress.com/effects-of-intravitreal-bevacizumab-on-reduced-visual-acuity-and-macul-a14263https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Kadir Eltutar, Fahreddin Acar, Nurhan Dincer, Sibel Zirtiloglu, Erkan Unsal Istanbul Training and Research Hospital, Istanbul, Turkey Background: The purpose of this study was to evaluate the effects of intravitreal bevacizumab injection in the treatment of macular thickness and reduced visual acuity in patients with branch retinal vein occlusion. Methods: In this retrospective study, we evaluated 15 eyes of 15 consecutive patients diagnosed with branch retinal vein occlusion between May 2008 and June 2011 at our institution. Detailed ophthalmologic examination, optical coherence tomography, and/or fundus fluorescein angiography was performed at diagnosis and during follow-up. A 1.25 mg intravitreal bevacizumab injection was administered to all patients on average 2.73 (1–7) times. Visual acuity and macular thickness were evaluated before and after treatment. Results: Eleven patients were female (73.3%) and four were male (26.6%). The mean patient age was 62.6 years. The patients were followed for a mean of 11.4 (range 4–24) months. Mean best-corrected visual acuity was 0.92 ± 0.52 logMAR (logarithm of the minimum angle of resolution) before treatment and 0.66 ± 0.42 logMAR at the last examination. The increase in visual acuity was found to be statistically significant (P = 0.031). Mean macular thickness was 395.46 ± 106.55 µm before treatment and 302.26 ± 84.6 µm after the final treatment. The decrease in macular thickness was statistically significant (P < 0.001). Conclusion: Intravitreal bevacizumab injection was effective for treatment of retinal vein branch occlusion. Keywords: branch retinal vein occlusion, bevacizumab, macular thickness, optical coherence tomographyEltutar KAcar FDincer NZirtiloglu SUnsal EDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2013, Iss default, Pp 1777-1780 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Eltutar K Acar F Dincer N Zirtiloglu S Unsal E Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
description	Kadir Eltutar, Fahreddin Acar, Nurhan Dincer, Sibel Zirtiloglu, Erkan Unsal Istanbul Training and Research Hospital, Istanbul, Turkey Background: The purpose of this study was to evaluate the effects of intravitreal bevacizumab injection in the treatment of macular thickness and reduced visual acuity in patients with branch retinal vein occlusion. Methods: In this retrospective study, we evaluated 15 eyes of 15 consecutive patients diagnosed with branch retinal vein occlusion between May 2008 and June 2011 at our institution. Detailed ophthalmologic examination, optical coherence tomography, and/or fundus fluorescein angiography was performed at diagnosis and during follow-up. A 1.25 mg intravitreal bevacizumab injection was administered to all patients on average 2.73 (1–7) times. Visual acuity and macular thickness were evaluated before and after treatment. Results: Eleven patients were female (73.3%) and four were male (26.6%). The mean patient age was 62.6 years. The patients were followed for a mean of 11.4 (range 4–24) months. Mean best-corrected visual acuity was 0.92 ± 0.52 logMAR (logarithm of the minimum angle of resolution) before treatment and 0.66 ± 0.42 logMAR at the last examination. The increase in visual acuity was found to be statistically significant (P = 0.031). Mean macular thickness was 395.46 ± 106.55 µm before treatment and 302.26 ± 84.6 µm after the final treatment. The decrease in macular thickness was statistically significant (P < 0.001). Conclusion: Intravitreal bevacizumab injection was effective for treatment of retinal vein branch occlusion. Keywords: branch retinal vein occlusion, bevacizumab, macular thickness, optical coherence tomography
format	article
author	Eltutar K Acar F Dincer N Zirtiloglu S Unsal E
author_facet	Eltutar K Acar F Dincer N Zirtiloglu S Unsal E
author_sort	Eltutar K
title	Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
title_short	Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
title_full	Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
title_fullStr	Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
title_full_unstemmed	Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
title_sort	effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/e4e3fc9a33de42bd8bbf69d9be4d4c90
work_keys_str_mv	AT eltutark effectsofintravitrealbevacizumabonreducedvisualacuityandmacularthicknesssecondarytobranchretinalveinocclusion AT acarf effectsofintravitrealbevacizumabonreducedvisualacuityandmacularthicknesssecondarytobranchretinalveinocclusion AT dincern effectsofintravitrealbevacizumabonreducedvisualacuityandmacularthicknesssecondarytobranchretinalveinocclusion AT zirtiloglus effectsofintravitrealbevacizumabonreducedvisualacuityandmacularthicknesssecondarytobranchretinalveinocclusion AT unsale effectsofintravitrealbevacizumabonreducedvisualacuityandmacularthicknesssecondarytobranchretinalveinocclusion
_version_	1718400502934274048

Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion

Ejemplares similares